Press Releases

Press Releases

Keyword Search

Date Title & Summary Additional Formats
10/13/20
Cidara Therapeutics to Present at the 2020 American College of Clinical Pharmacy (ACCP) Annual Meeting
SAN DIEGO , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two posters at
PDF Version
09/14/20
Cidara Therapeutics to Present New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020
SAN DIEGO , Sept. 14, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two oral
PDF Version
09/02/20
Cidara Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein , Ph.D., President and
PDF Version
08/13/20
Cidara Provides Corporate Update and Reports Second Quarter 2020 Financial Results
SAN DIEGO , Aug. 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended
PDF Version
08/04/20
Cidara Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
SAN DIEGO , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein , Ph.D., President and
PDF Version
07/27/20
Cidara Therapeutics Announces Formation of Scientific Advisory Board
Comprised of World-Renowned Experts in Virology, Fungal Diseases and Hematology SAN DIEGO , July 27, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or
PDF Version
07/17/20
Cidara Therapeutics to Participate in B. Riley Virtual Summer Series Panel on Antiviral Therapeutics
SAN DIEGO , July 17, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein , Ph.D., President and
PDF Version
06/29/20
Cidara Therapeutics Added to Russell 3000® Index
SAN DIEGO , June 29, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been added to the Russell 3000®
PDF Version
06/23/20
Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19
SAN DIEGO , June 23, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein , Ph.D., President and
PDF Version
06/11/20
Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference
SAN DIEGO , June 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein , Ph.D., President and
PDF Version